- Country: USA
- Summary: Technology/Business Opportunity Drug Delivery with Carbon Nanotube Porins
- UST Ref No: 81319241
- Deadline: 10 Apr 2023
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: IL-13451
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
Opportunity:
Lawrence Livermore National Laboratory (LLNL), operated by the Lawrence Livermore National Security (LLNS), LLC under contract no. DE-AC52-07NA27344 (Contract 44) with the U.S. Department of Energy (DOE), is offering the opportunity to enter into a collaboration to commercialize its drug delivery with carbon nanotube porins technology.
Background:
There is a high demand for novel technologies for efficient drug delivery, particularly in chemotherapy where delivering drugs into unhealthy cells is still quite difficult. Liposomes, which are spherical vesicles characterized by a bilayer of lipids with an internal aqueous cavity, constitute one class of vehicles for drug delivery. The US FDA has approved several liposomal formulations for the delivery of drugs for the treatment of various disorders, but challenges still remain particularly in the delivery of chemotherapeutic agents that are associated with toxicity.
Description:
To address shortcomings of current liposome drug delivery systems, the patented innovation uses drug-loaded liposomes containing carbon nanotube porins (CNTPs) inserted into the liposomal membranes for the delivery of the encapsulated drugs. Short CNTPs (10 nm in length) with narrow diameter (0.8 nm) has been demonstrated to facilitate efficient fusion of lipid bilayers resulting in the complete mixing of the membrane material and vesicle interior content. Drugs encapsulated in the liposome decorated with CNTPs are released into the cytoplasm of the cell upon fusion of the liposomal membrane with the cell membrane.
For proof-of-concept, the delivery of doxorubicin (DOX), a powerful anti-cancer drug that has significant cardiac toxicity in free form, was tested. Scientists used CNTPs to directly introduce DOX from spherical sacs of liposomes through the cell plasma membrane into its interior. Controls such as buffer, CNTP in free form, liposomes with CNTPs on the surface but no DOX, and DOX... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINTechnology/Business Opportunity Drug Delivery with Carbon Nanotube Porins - USA Tender
The ENERGY, DEPARTMENT OF, a Government sector organization in USA, has announced a new tender for Technology/Business Opportunity Drug Delivery with Carbon Nanotube Porins. This tender is published on USARFP under UST Ref No: 81319241 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2023-04-10.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
